Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Q&A: María Berrocal's Ingrid Kreissig Award Lecture at EURETINA 2025

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

 Optain Health secures $26 million Series A funding

Q&A: Marion Munk on IntRIS symposium at EURETINA 2025

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

Researchers propose new explanation for drusen regression without atrophy

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Advanced Solutions for Retinal Vascular Diseases: Achieving Superior Outcomes with Durable Treatments

Video Series

A Case of Neovascular AMD with Persistent Subretinal Fluid

Videos

A panel expert retina specialists present challengingcases of neovascular AMD and DME and have a comprehensive discussion on the benefits of novel durable treatments.

Adiel Smith, MD, FASRS, presents the case of a patient with neovascular age-related macular degeneration (nAMD) with treatment-resistant pigment epithelium detachment, and the panel offers clinical insights on treatment decisions.

A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment

Jaclyn Kovach, MD, FASRS, presents the case of a patient with neovascular AMD with persistent subretinal fluid, and members of the panel share their experiences treating similar patients.

Katherine Talcott, MD, presents the case of a patient with diabetic macular edema, and the rest of the panel share their clinical experiences and discuss factors that inform the utilization of more durable agents.

Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

Greg Budoff, MD, presents the case of a patient with diabetic macular edema who achieved extended treatment interval, and the panel discusses treatment considerations, including the role of PRN regimens.

A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy

Expert retina speclialists discuss evolving treatment paradigms and the role of intravitreal steroids and macular laser for treating diabetic macular edema.

Evolving Role of Steroids and Laser In DME

The panel concludes its discussion with thoughts on the profound impact durable treatments have on the quality of life of patients with retinal diseases.

Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases

A Case of Neovascular AMD with Persistent Subretinal Fluid

EP: 1.A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment

EP: 2.A Case of Neovascular AMD with Persistent Subretinal Fluid

EP: 3.Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

EP: 4.A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy

EP: 5.Evolving Role of Steroids and Laser In DME

EP: 6.Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases

Newsletter